Navigation Links
LA BioMed's Dr. Ronald Oudiz impacting lives of those with pulmonary hypertension
Date:10/31/2011

LOS ANGELES (Oct. 31, 2011) Pulmonary arterial hypertension (PAH) is a rare form of pulmonary hypertension (PH) that affects between 500-1,000 people each year - or 1 or 2 people out of one million people worldwide per year - most of whom are young women between the ages of 20 and 40. While the numbers may not seem significant, the disease itself has been a paradox for physician-researchers since in many cases, the causes of PAH remain unknown.

As the month of November kicks off PH Awareness Month, Dr. Ronald Oudiz lead investigator at the Los Angeles Biomedical Research Institute (LA BioMed) hopes to bring greater awareness to this disorder that has affected the lives of so many. Dr. Oudiz is a pioneer in this field, having received the 2011 Award for Excellence earlier this year from the Pulmonary Hypertension Association for his dedication to find new ways to treat this often fatal disease.

PAH is an increase in blood pressure in the pulmonary artery, pulmonary vein or pulmonary capillaries that can lead to shortness of breath, dizziness or fainting. At its worst, PAH can be a severe disease with a markedly decreased exercise tolerance and can lead to heart failure and death. Most recently, Dr. Oudiz applied the concept of cardiopulmonary exercise testing (CPET) as a way to noninvasively measure physiologic changes at rest and during exercise that are reflective in abnormalities of PAH, heart failure, and various lung diseases. He is one of the first physician-researchers to apply this concept to PAH patients.

"Pulmonary hypertension is still considered a rare disease, impacting less than 200,000 people worldwide," said Dr. Oudiz. "Over the last decade, however, there have been significant advances in diagnosing and treating patients both through exercise and with the proper medication, and it is my goal to not only increase awareness but also to improve the lives of patients diagnosed with PAH."

In a recent study, Dr. Oudiz and his team of researchers looked at the long-term effects of medication in the treatment of PAH and discovered that certain medications can help improve the health of PAH patients. Dr. Oudiz found that the health and exercise capacity of PAH patients improved after two years of treatment with an FDA-approved drug called ambrisentan, an orally-active, once-daily medication that helps improve exercise capacity, as well as other clinical indications of PAH disease severity, including clinical worsening.

Dr. Oudiz currently serves as the director of LA BioMed's PH Clinical Trials Center, where he and his team engage patients in exercise therapy, provide educational literature and videos to patients and their families, and continue to study novel therapies for PH. Dr. Oudiz is also a member of several steering committees that are helping to design multi-center clinical trials involving worldwide PH centers, whose common goal is to find better ways to take care of their patients.

For PH Awareness Month, LA BioMed's PH Clinical Trials Center will host group meetings and bring in guest speakers to give patients hope, a sense of camaraderie, and much-needed support as they find ways to cope with this debilitating disease.


'/>"/>

Contact: Diana Soltesz
diana@dsmmedia.com
818-592-6747
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert

Related medicine news :

1. Launching Five Clinics on Wheels This Year, Ronald McDonald House Charities Celebrates Ten Years of the Ronald McDonald Care Mobile Program
2. Groundbreaking Principal and Contributor on Dr. Oz Show Releases His Latest Book on How We Can Influence the Lives of Children
3. Behavioral therapy improves sleep and lives of patients with pain
4. 29 Clear Channel stations Nationwide Raise Nearly $2.8 Million to Help Save the Lives of Kids Fighting Cancer and Other Deadly Diseases
5. Rising Use of Medical Technologies Extending Americans Lives
6. Your Vote Can Make a Difference in the Lives of Thousands of Tennesseans
7. Saving lives one breath at a time
8. Kidney Donors Go On to Lead Long, Healthy Lives
9. High School Student's College Prerequisite: Save Five Thousand Lives in Africa. Teen Supports Nothing But Nets in Malaria Fight
10. Difficulty trusting and reaching out to others may shorten diabetes patients lives
11. Widespread Public Defibrillators May Save Lives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... ... feature 150+ Hospital and Health System Executive Speakers including: , , ... of the United States of America: George W. Bush , Boxing Legend, Successful ... Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber McGraw Walsh , ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... help improve all aspects of people’s health and nutrition, announced its product Leyzene ... , Natural Subsistence develops nutritional supplements that help people improve all aspects ...
(Date:3/23/2017)... ... 2017 , ... The American Board of Quality Assurance and Utilization Review Physicians ... to Health Care Quality and Management and Patient Safety. , It is with appreciation ... but also to the Health Care Quality and Patient Safety movements. Diplomates and Members ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... the New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April 4, ... How will the new EU MDR language change the way manufacturers approach ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... “Beyond and ... “Beyond and Back” is the creation of published author Bonetta Rose, a wife, mother ... our lives. , Published by Christian Faith Publishing, Bonetta Rose‘s new book presents actual ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , March 23, 2017 ... Enterprises Limited, anuncia el nombramiento de Stuart ... una plataforma de servicios integrados completa para su ... un cargo clave en el crecimiento y ejecución ... será responsable de impulsar todas las actividades de ...
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
(Date:3/23/2017)... March 23, 2017 /PRNewswire/ - Medicure Inc. ("Medicure" ... specialty pharmaceutical company, is pleased to announce that ... approval from the U.S. Food and Drug Administration ... ("ANDA") for tetrabenazine tablets in the 12.5 mg ... is a generic equivalent of the branded product ...
Breaking Medicine Technology: